Cargando…
Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period
AIM: To investigate seven CA125 criteria to monitor progressive ovarian cancer among patients with stage IC–IV disease. MATERIALS & METHODS: Four criteria were used to asses CA125 increments starting from concentrations ≥35 U/ml and three criteria to asses increments starting from concentrations...
Autores principales: | Abu Hassan, Suher O, Nielsen, Dorte L, Tuxen, Malgorzata K, Petersen, Per H, Sölétormos, György |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583662/ https://www.ncbi.nlm.nih.gov/pubmed/28884012 http://dx.doi.org/10.4155/fsoa-2017-0023 |
Ejemplares similares
-
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001) -
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers
por: Sölétormos, György, et al.
Publicado: (2016) -
Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer
por: Kristiansen, Søren, et al.
Publicado: (2015) -
Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer
por: Kristiansen, Søren, et al.
Publicado: (2016) -
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
por: Gronlund, B, et al.
Publicado: (2004)